[10] reported that GPX4 inhibition has potent activity to suppress survival of DTP cells, including those generated from HER2‐amplified breast cancer, EGFR‐mutated lung cancer, and BRAF‐mutated melanoma cells. This evidence concerns the gene EGFR and lung carcinoma.